false 0001799788 0001799788 2024-12-19 2024-12-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) December 19, 2024

 

Greenwich LifeSciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39555   20-5473709

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I. R. S. Employer

Identification No.)

 

3992 Bluebonnet Dr, Building 14

Stafford, TX 77477

(Address of principal executive offices, including ZIP code)

 

(832) 819-3232

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   GLSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On December 19, 2024, Greenwich LifeSciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 12,848,165 shares of common stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on November 1, 2024 are as follows:

 

Proposal 1. All of the five (5) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows:

 

Directors  For   Against   Abstain   Broker Non Vote 
David McWilliams   7,824,313    0    408,663    1,004,439 
Snehal S. Patel   8,052,306    0    184,934    1,000,175 
Eric Rothe   7,849,736    0    383,240    1,004,439 
F. Joseph Daugherty, M.D.   7,987,061    0    245,915    1,004,439 
Kenneth Hallock   7,852,855    0    380,121    1,004,439 

 

Proposal 2. The appointment of RBSM, LLP as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2024 was ratified and approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote 
 9,224,694    10,077    2,644    0 

 

Proposal 3. The amendment to the Company’s 2019 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance under such plan to 4,000,000 shares from 1,500,000 shares was ratified and approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote 
 8,067,672    164,730    5,043    999,970 

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Greenwich LifeSciences, Inc.
     
Date: December 19, 2024 By:  /s/ Snehal Patel
    Snehal Patel
    Chief Executive Officer

 

-3-

 

v3.24.4
Cover
Dec. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 19, 2024
Entity File Number 001-39555
Entity Registrant Name Greenwich LifeSciences, Inc.
Entity Central Index Key 0001799788
Entity Tax Identification Number 20-5473709
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3992 Bluebonnet Dr
Entity Address, Address Line Two Building 14
Entity Address, City or Town Stafford
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77477
City Area Code (832)
Local Phone Number 819-3232
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol GLSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Greenwich LifeSciences (NASDAQ:GLSI)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Greenwich LifeSciences
Greenwich LifeSciences (NASDAQ:GLSI)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Greenwich LifeSciences